방사선생물학

본문글자크기
  • [Head Neck.] Synergistic anticancer activity of sorafenib, paclitaxel, and radiation therapy on anaplastic thyroid cancer in vitro and in vivo

    [Head Neck.] Synergistic anticancer activity of sorafenib, paclitaxel, and radiation therapy on anaplastic thyroid cancer in vitro and in vivo

    연세의대 / 김수영, 장항석, 이용상*

  • 출처
    Head Neck.
  • 등재일
    2020 Dec
  • 저널이슈번호
    42(12):3678-3684. doi: 10.1002/hed.26431. Epub 2020 Sep 8.
  • 내용

    바로가기  >

    Abstract
    Background: This study aimed to investigate the antitumor activity of paclitaxel with radiation and sorafenib in anaplastic thyroid cancer (ATC) cells in vitro and in vivo.

    Methods: The 8505C ATC cell line was exposed to radiation, sorafenib, and paclitaxel each or in combination. The effects of combined treatment on the cell cycle and intracellular signaling pathways were assessed using flow cytometry and western blot analysis. An ATC cell line xenograft model was used to examine antitumor activity in vivo.

    Results: Radiation, paclitaxel plus sorafenib synergistically decreased cell viability in ATC cells and significantly increased apoptotic cell death. The combination of paclitaxel, sorafenib with radiation reduced the antiapoptotic factor in ATC. This combination therapy significantly reduced the tumor volume and increased survival in the ATC xenograft model.

    Conclusions: These results suggest that the combination of radiation and paclitaxel plus sorafenib has significant anticancer activity in preclinical models.

     

     

     

     

     

    Affiliations

    Soo Young Kim  1 , Seok-Mo Kim  1 , Hojin Chang  1 , Hang-Seok Chang  1 , Cheong Soo Park  2 , Yong Sang Lee  1
    1 Department of Surgery, Thyroid Cancer Center, Gangnam Severance Hospital, Institute of Refractory Thyroid Cancer, Yonsei University College of Medicine, Seoul, South Korea.
    2 Department of Surgery, CHA Ilsan Medical Center, Goyang, South Korea.

  • 키워드
    https://pubmed.ncbi.nlm.nih.gov/32896015/
  • 연구소개
    본 연구에서는 갑상선암 중에서 aggressive하고 예후가 좋지 않은 미분화 갑상선암 (anaplastic thyroid cancer, ATC)에서 항암치료, 방사선치료와 표적치료 복합요법의 효과에 대해 알아보았습니다. Paclitaxel 항암제와, 방사선치료, 갑상선에서 사용승인된 tyrosine-kinase inhibitor인 sorafenib을 복합요법으로 사용하여 8505 ATC cell line에서 상승 작용 및 관련 기전에 대해 연구하였습니다. 현재 ATC 표준 치료는 없으며, 미국 갑상선학회 가이드라인에서도 항암치료, 방사선치료, 수술을 권유하는 것 외에는 정확한 프로토콜은 없는 상황에서 preclinical모델일지라도, 복합요법에 대한 연구가 앞으로 임상에서 환자를 치료하는데 도움이 될 것 같아 소개합니다.
  • 덧글달기
    덧글달기
       IP : 44.200.175.255

    등록